Norepinephrine (Levophed) Receptor Activity and Dose-Dependent Effects
Norepinephrine predominantly stimulates alpha-1 adrenergic receptors at all therapeutic doses, with consistent beta-1 activity that remains relatively stable across the dosing range, unlike epinephrine which shows clear dose-dependent receptor shifts. 1
Primary Receptor Profile
Norepinephrine acts primarily as an alpha-1 agonist with significant beta-1 activity but minimal beta-2 effects at any dose. 2, 3
Alpha-1 receptors: Norepinephrine potently stimulates alpha-1 adrenergic receptors throughout its entire dosing range, producing peripheral vasoconstriction and increased systemic vascular resistance 1, 2
Beta-1 receptors: Norepinephrine provides consistent beta-1 receptor stimulation that helps preserve or increase cardiac output while producing vasoconstriction 1, 2
Beta-2 receptors: Unlike epinephrine, norepinephrine has minimal beta-2 activity and does not produce the vasodilation seen with low-dose epinephrine 1
Dose-Dependent Receptor Changes
The critical distinction is that norepinephrine does NOT exhibit the dramatic dose-dependent receptor shift seen with epinephrine—its alpha-1 predominance remains constant across therapeutic doses. 1
Standard Dosing Range (0.05-3.0 mcg/kg/min)
Norepinephrine maintains its alpha-1 predominant profile throughout the typical infusion range of 2-20 mcg/kg/min used in shock states 4
The balance between alpha-1 vasoconstriction and beta-1 cardiac stimulation remains relatively stable, though higher doses intensify both effects proportionally 1
At all therapeutic doses, alpha-1 effects dominate the hemodynamic response, producing consistent increases in systemic vascular resistance and blood pressure 1, 2
Contrast with Epinephrine's Dose-Dependent Profile
This is fundamentally different from epinephrine, which shows clear dose-dependent receptor transitions:
Low-dose epinephrine (<0.3 mcg/kg/min): Predominantly beta-2 effects with vasodilation and decreased systemic vascular resistance 5
High-dose epinephrine (>0.3 mcg/kg/min): Alpha-1 effects become dominant, causing vasoconstriction 5
Norepinephrine lacks this beta-2 mediated vasodilation at any dose, maintaining alpha-1 predominance throughout 1
Cardiovascular Effects Across Doses
Cardiac Effects (Beta-1 Mediated)
Norepinephrine increases stroke volume and coronary blood flow through beta-1 and coronary vessel beta-2 receptor stimulation 1
The positive chronotropic effects are often counterbalanced by vagal reflex activity from increased blood pressure, preventing excessive tachycardia 1
These cardiac effects remain relatively consistent across the dosing range, though they may be transient and time-dependent 1
Vascular Effects (Alpha-1 Mediated)
Peripheral vasoconstriction and increased systemic vascular resistance occur at all doses 1
Norepinephrine increases pulmonary artery pressure and pulmonary vascular resistance similarly to epinephrine 1
The drug increases venous return by shifting unstressed to stressed volume, which can transiently increase cardiac output 1
Clinical Implications by Dose
Low to Moderate Doses (0.05-0.3 mcg/kg/min)
Provide alpha-1 mediated vasoconstriction with preserved cardiac output through beta-1 activity 1, 2
First-line choice for vasodilatory (septic) shock where both pressure support and cardiac output maintenance are needed 2
Higher Doses (>0.3 mcg/kg/min)
Intensify both alpha-1 vasoconstriction and beta-1 cardiac stimulation proportionally 1
At very high doses, excessive vasoconstriction may impair splanchnic and renal perfusion 1
Unlike high-dose dopamine (10-20 mcg/kg/min), which increases MAP primarily through cardiac output, norepinephrine maintains its vasoconstrictive mechanism 1
Important Clinical Caveats
The key pitfall is assuming norepinephrine behaves like epinephrine with dose-dependent receptor shifts—it does not. 1
Norepinephrine's alpha-1 predominance is consistent across all therapeutic doses, making it predictably vasoconstrictive 1, 2
Extravasation causes severe tissue necrosis at any dose; phentolamine (0.1-0.2 mg/kg up to 10 mg diluted in 10 mL saline) should be infiltrated locally if extravasation occurs 4
The effects on cardiac output are inconsistent and time-dependent, potentially related to baseline cardiovascular state and ventriculo-arterial coupling 1
At high doses, regional perfusion (splanchnic, renal) may be compromised despite adequate blood pressure 1